{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:09:57Z","timestamp":1791875397052,"version":"4.3.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,5,15]],"date-time":"2018-05-15T00:00:00Z","timestamp":1526342400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Sciences Foundation of China","doi-asserted-by":"crossref","award":["81600151"],"award-info":[{"award-number":["81600151"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Shanghai Municipal Bureau of health and Family Planning Commission","award":["Grants 20154Y0168"],"award-info":[{"award-number":["Grants 20154Y0168"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s00277-018-3368-8","type":"journal-article","created":{"date-parts":[[2018,5,15]],"date-time":"2018-05-15T16:43:14Z","timestamp":1526402594000},"page":"1327-1335","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic review"],"prefix":"10.1007","volume":"97","author":[{"given":"Zhen","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rufang","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Qing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunxiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lining","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongming","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanfei","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zizhen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junmin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,15]]},"reference":[{"issue":"26","key":"3368_CR1","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","volume":"127","author":"JN Brudno","year":"2016","unstructured":"Brudno JN, Kochenderfer JN (2016) Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 127(26):3321\u20133330. \n                    https:\/\/doi.org\/10.1182\/blood-2016-04-703751","journal-title":"Blood"},{"issue":"12","key":"3368_CR2","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","volume":"119","author":"JN Kochenderfer","year":"2012","unstructured":"Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes MS, Sherry RM, Yang JC, Kammula US, Devillier L, Carpenter R, Nathan DA, Morgan RA, Laurencot C, Rosenberg SA (2012) B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119(12):2709\u20132720. \n                    https:\/\/doi.org\/10.1182\/blood-2011-10-384388","journal-title":"Blood"},{"issue":"18","key":"3368_CR3","doi-asserted-by":"publisher","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","volume":"118","author":"RJ Brentjens","year":"2011","unstructured":"Brentjens RJ, Riviere I, Park JH, Davila ML, Wang X, Stefanski J, Taylor C, Yeh R, Bartido S, Borquez-Ojeda O, Olszewska M, Bernal Y, Pegram H, Przybylowski M, Hollyman D, Usachenko Y, Pirraglia D, Hosey J, Santos E, Halton E, Maslak P, Scheinberg D, Jurcic J, Heaney M, Heller G, Frattini M, Sadelain M (2011) Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118(18):4817\u20134828. \n                    https:\/\/doi.org\/10.1182\/blood-2011-04-348540","journal-title":"Blood"},{"issue":"1","key":"3368_CR4","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","volume":"25","author":"FL Locke","year":"2017","unstructured":"Locke FL, Neelapu SS, Bartlett NL, Siddiqi T, Chavez JC, Hosing CM, Ghobadi A, Budde LE, Bot A, Rossi JM, Jiang Y, Xue AX, Elias M, Aycock J, Wiezorek J, Go WY (2017) Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol Ther : J Am Soc Gene Ther 25(1):285\u2013295. \n                    https:\/\/doi.org\/10.1016\/j.ymthe.2016.10.020","journal-title":"Mol Ther : J Am Soc Gene Ther"},{"issue":"17","key":"3368_CR5","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1182\/blood-2013-06-506741","volume":"122","author":"CR Cruz","year":"2013","unstructured":"Cruz CR, Micklethwaite KP, Savoldo B, Ramos CA, Lam S, Ku S, Diouf O, Liu E, Barrett AJ, Ito S, Shpall EJ, Krance RA, Kamble RT, Carrum G, Hosing CM, Gee AP, Mei Z, Grilley BJ, Heslop HE, Rooney CM, Brenner MK, Bollard CM, Dotti G (2013) Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood 122(17):2965\u20132973. \n                    https:\/\/doi.org\/10.1182\/blood-2013-06-506741","journal-title":"Blood"},{"issue":"11","key":"3368_CR6","doi-asserted-by":"publisher","first-page":"e1027469","DOI":"10.1080\/2162402X.2015.1027469","volume":"4","author":"H Dai","year":"2015","unstructured":"Dai H, Zhang W, Li X, Han Q, Guo Y, Zhang Y, Wang Y, Wang C, Shi F, Zhang Y, Chen M, Feng K, Wang Q, Zhu H, Fu X, Li S, Han W (2015) Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia. Oncoimmunology 4(11):e1027469. \n                    https:\/\/doi.org\/10.1080\/2162402X.2015.1027469","journal-title":"Oncoimmunology"},{"issue":"10","key":"3368_CR7","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","volume":"34","author":"JN Brudno","year":"2016","unstructured":"Brudno JN, Somerville RP, Shi V, Rose JJ, Halverson DC, Fowler DH, Gea-Banacloche JC, Pavletic SZ, Hickstein DD, Lu TL, Feldman SA, Iwamoto AT, Kurlander R, Maric I, Goy A, Hansen BG, Wilder JS, Blacklock-Schuver B, Hakim FT, Rosenberg SA, Gress RE, Kochenderfer JN (2016) Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J Clin Oncol : Off J Am Soc Clin Oncol 34(10):1112\u20131121. \n                    https:\/\/doi.org\/10.1200\/JCO.2015.64.5929","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"issue":"24","key":"3368_CR8","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1182\/blood-2015-12-686725","volume":"127","author":"X Wang","year":"2016","unstructured":"Wang X, Popplewell LL, Wagner JR, Naranjo A, Blanchard MS, Mott MR, Norris AP, Wong CW, Urak RZ, Chang WC, Khaled SK, Siddiqi T, Budde LE, Xu J, Chang B, Gidwaney N, Thomas SH, Cooper LJ, Riddell SR, Brown CE, Jensen MC, Forman SJ (2016) Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL. Blood 127(24):2980\u20132990. \n                    https:\/\/doi.org\/10.1182\/blood-2015-12-686725","journal-title":"Blood"},{"issue":"9","key":"3368_CR9","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1172\/JCI86721","volume":"126","author":"P Kebriaei","year":"2016","unstructured":"Kebriaei P, Singh H, Huls MH, Figliola MJ, Bassett R, Olivares S, Jena B, Dawson MJ, Kumaresan PR, Su S, Maiti S, Dai J, Moriarity B, Forget MA, Senyukov V, Orozco A, Liu T, McCarty J, Jackson RN, Moyes JS, Rondon G, Qazilbash M, Ciurea S, Alousi A, Nieto Y, Rezvani K, Marin D, Popat U, Hosing C, Shpall EJ, Kantarjian H, Keating M, Wierda W, Do KA, Largaespada DA, Lee DA, Hackett PB, Champlin RE, Cooper LJ (2016) Phase I trials using sleeping beauty to generate CD19-specific CAR T cells. J Clin Invest 126(9):3363\u20133376. \n                    https:\/\/doi.org\/10.1172\/jci86721","journal-title":"J Clin Invest"},{"issue":"5","key":"3368_CR10","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1172\/JCI46110","volume":"121","author":"B Savoldo","year":"2011","unstructured":"Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G, Kamble RT, Bollard CM, Gee AP, Mei Z, Liu H, Grilley B, Rooney CM, Heslop HE, Brenner MK, Dotti G (2011) CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 121(5):1822\u20131826. \n                    https:\/\/doi.org\/10.1172\/jci46110","journal-title":"J Clin Invest"},{"issue":"25","key":"3368_CR11","doi-asserted-by":"publisher","first-page":"4129","DOI":"10.1182\/blood-2013-08-519413","volume":"122","author":"JN Kochenderfer","year":"2013","unstructured":"Kochenderfer JN, Dudley ME, Carpenter RO, Kassim SH, Rose JJ, Telford WG, Hakim FT, Halverson DC, Fowler DH, Hardy NM, Mato AR, Hickstein DD, Gea-Banacloche JC, Pavletic SZ, Sportes C, Maric I, Feldman SA, Hansen BG, Wilder JS, Blacklock-Schuver B, Jena B, Bishop MR, Gress RE, Rosenberg SA (2013) Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 122(25):4129\u20134139. \n                    https:\/\/doi.org\/10.1182\/blood-2013-08-519413","journal-title":"Blood"},{"issue":"224","key":"3368_CR12","doi-asserted-by":"publisher","first-page":"224ra225","DOI":"10.1126\/scitranslmed.3008226","volume":"6","author":"ML Davila","year":"2014","unstructured":"Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, Chung SS, Stefanski J, Borquez-Ojeda O, Olszewska M, Qu J, Wasielewska T, He Q, Fink M, Shinglot H, Youssif M, Satter M, Wang Y, Hosey J, Quintanilla H, Halton E, Bernal Y, Bouhassira DC, Arcila ME, Gonen M, Roboz GJ, Maslak P, Douer D, Frattini MG, Giralt S, Sadelain M, Brentjens R (2014) Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 6(224):224ra225. \n                    https:\/\/doi.org\/10.1126\/scitranslmed.3008226","journal-title":"Sci Transl Med"},{"issue":"16","key":"3368_CR13","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, Mahnke YD, Melenhorst JJ, Rheingold SR, Shen A, Teachey DT, Levine BL, June CH, Porter DL, Grupp SA (2014) Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371(16):1507\u20131517. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1407222","journal-title":"N Engl J Med"},{"issue":"9967","key":"3368_CR14","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, Steinberg SM, Stroncek D, Tschernia N, Yuan C, Zhang H, Zhang L, Rosenberg SA, Wayne AS, Mackall CL (2015) T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385(9967):517\u2013528. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(14)61403-3","journal-title":"Lancet"},{"issue":"6","key":"3368_CR15","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","volume":"33","author":"JN Kochenderfer","year":"2015","unstructured":"Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, Yang JC, Phan GQ, Hughes MS, Sherry RM, Raffeld M, Feldman S, Lu L, Li YF, Ngo LT, Goy A, Feldman T, Spaner DE, Wang ML, Chen CC, Kranick SM, Nath A, Nathan DA, Morton KE, Toomey MA, Rosenberg SA (2015) Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol : Off J Am Soc Clin Oncol 33(6):540\u2013549. \n                    https:\/\/doi.org\/10.1200\/JCO.2014.56.2025","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"issue":"303","key":"3368_CR16","doi-asserted-by":"publisher","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","volume":"7","author":"DL Porter","year":"2015","unstructured":"Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Loren AW, Bagg A, Marcucci KT, Shen A, Gonzalez V, Ambrose D, Grupp SA, Chew A, Zheng Z, Milone MC, Levine BL, Melenhorst JJ, June CH (2015) Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med 7(303):303ra139. \n                    https:\/\/doi.org\/10.1126\/scitranslmed.aac5415","journal-title":"Sci Transl Med"},{"issue":"6","key":"3368_CR17","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI85309","volume":"126","author":"CJ Turtle","year":"2016","unstructured":"Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, Sommermeyer D, Melville K, Pender B, Budiarto TM, Robinson E, Steevens NN, Chaney C, Soma L, Chen X, Yeung C, Wood B, Li D, Cao J, Heimfeld S, Jensen MC, Riddell SR, Maloney DG (2016) CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest 126(6):2123\u20132138. \n                    https:\/\/doi.org\/10.1172\/JCI85309","journal-title":"J Clin Invest"},{"issue":"355","key":"3368_CR18","doi-asserted-by":"publisher","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","volume":"8","author":"CJ Turtle","year":"2016","unstructured":"Turtle CJ, Hanafi LA, Berger C, Hudecek M, Pender B, Robinson E, Hawkins R, Chaney C, Cherian S, Chen X, Soma L, Wood B, Li D, Heimfeld S, Riddell SR, Maloney DG (2016) Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med 8(355):355ra116. \n                    https:\/\/doi.org\/10.1126\/scitranslmed.aaf8621","journal-title":"Sci Transl Med"},{"key":"3368_CR19","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1158\/1078-0432.CCR-16-1799","volume":"23","author":"Y Hu","year":"2016","unstructured":"Hu Y, Wu Z, Luo Y, Shi J, Yu J, Pu C, Liang Z, Wei G, Cui Q, Sun J, Jiang J, Xie J, Tan Y, Ni W, Tu J, Wang J, Jin A, Zhang H, Cai Z, Xiao L, Huang H (2016) Potent anti-leukemia activities of chimeric antigen receptor modified T cells against CD19 in Chinese patients with relapsed\/refractory acute lymphocytic leukemia. Clin Cancer Res : Off J Am Assoc Cancer Res 23:3297\u20133306. \n                    https:\/\/doi.org\/10.1158\/1078-0432.ccr-16-1799","journal-title":"Clin Cancer Res : Off J Am Assoc Cancer Res"},{"issue":"16","key":"3368_CR20","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","volume":"35","author":"JN Kochenderfer","year":"2017","unstructured":"Kochenderfer JN, Somerville RPT, Lu T, Shi V, Bot A, Rossi J, Xue A, Goff SL, Yang JC, Sherry RM, Klebanoff CA, Kammula US, Sherman M, Perez A, Yuan CM, Feldman T, Friedberg JW, Roschewski MJ, Feldman SA, McIntyre L, Toomey MA, Rosenberg SA (2017) Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels. J Clin Oncol : Off J Am Soc Clin Oncol 35(16):1803\u20131813. \n                    https:\/\/doi.org\/10.1200\/JCO.2016.71.3024","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"issue":"1","key":"3368_CR21","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1182\/asheducation-2016.1.567","volume":"2016","author":"NV Frey","year":"2016","unstructured":"Frey NV, Porter DL (2016) Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia. Hematol Ed Program Ame Soc Hematol Am Soc Hematol Ed Program 2016(1):567\u2013572. \n                    https:\/\/doi.org\/10.1182\/asheducation-2016.1.567","journal-title":"Hematol Ed Program Ame Soc Hematol Am Soc Hematol Ed Program"},{"issue":"2","key":"3368_CR22","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2217\/imt-2016-0127","volume":"9","author":"F Anwer","year":"2017","unstructured":"Anwer F, Shaukat AA, Zahid U, Husnain M, McBride A, Persky D, Lim M, Hasan N, Riaz IB (2017) Donor origin CAR T cells: graft versus malignancy effect without GVHD, a systematic review. Immunotherapy 9(2):123\u2013130. \n                    https:\/\/doi.org\/10.2217\/imt-2016-0127","journal-title":"Immunotherapy"},{"issue":"2","key":"3368_CR23","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","volume":"44","author":"OU Kawalekar","year":"2016","unstructured":"Kawalekar OU, O'Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey AD Jr, Patel PR, Guedan S, Scholler J, Keith B, Snyder N, Blair I, Milone MC, June CH (2016) Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity 44(2):380\u2013390. \n                    https:\/\/doi.org\/10.1016\/j.immuni.2016.01.021","journal-title":"Immunity"},{"issue":"3","key":"3368_CR24","doi-asserted-by":"publisher","first-page":"911","DOI":"10.4049\/jimmunol.1402346","volume":"194","author":"K Watanabe","year":"2015","unstructured":"Watanabe K, Terakura S, Martens AC, van Meerten T, Uchiyama S, Imai M, Sakemura R, Goto T, Hanajiri R, Imahashi N, Shimada K, Tomita A, Kiyoi H, Nishida T, Naoe T, Murata M (2015) Target antigen density governs the efficacy of anti-CD20-CD28-CD3 zeta chimeric antigen receptor-modified effector CD8+ T cells. J Immunol (Baltimore, Md : 1950) 194(3):911\u2013920. \n                    https:\/\/doi.org\/10.4049\/jimmunol.1402346","journal-title":"J Immunol (Baltimore, Md : 1950)"},{"issue":"6","key":"3368_CR25","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","volume":"6","author":"DT Teachey","year":"2016","unstructured":"Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Maude SL, Frey N, Pequignot E, Gonzalez VE, Chen F, Finklestein J, Barrett DM, Weiss SL, Fitzgerald JC, Berg RA, Aplenc R, Callahan C, Rheingold SR, Zheng Z, Rose-John S, White JC, Nazimuddin F, Wertheim G, Levine BL, June CH, Porter DL, Grupp SA (2016) Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov 6(6):664\u2013679. \n                    https:\/\/doi.org\/10.1158\/2159-8290.CD-16-0040","journal-title":"Cancer Discov"},{"issue":"21","key":"3368_CR26","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","volume":"130","author":"KA Hay","year":"2017","unstructured":"Hay KA, Hanafi LA, Li D, Gust J, Liles WC, Wurfel MM, Lopez JA, Chen J, Chung D, Harju-Baker S, Cherian S, Chen X, Riddell SR, Maloney DG, Turtle CJ (2017) Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood 130(21):2295\u20132306. \n                    https:\/\/doi.org\/10.1182\/blood-2017-06-793141","journal-title":"Blood"},{"key":"3368_CR27","unstructured":"David MB, Nathan S, Ted JH, Zachary G, Stephan AG (2016) Interleukin 6 is not made by chimeric antigen receptor T cells and does not impact their function. 58th Am Soc Hematol Annu Meet Exposition \n                    https:\/\/ash.confex.com\/ash\/2016\/webprogram\/Paper92806.html"},{"issue":"1","key":"3368_CR28","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.bbcan.2015.12.001","volume":"1865","author":"M Norelli","year":"2016","unstructured":"Norelli M, Casucci M, Bonini C, Bondanza A (2016) Clinical pharmacology of CAR-T cells: linking cellular pharmacodynamics to pharmacokinetics and antitumor effects. Biochim Biophys Acta 1865(1):90\u2013100. \n                    https:\/\/doi.org\/10.1016\/j.bbcan.2015.12.001","journal-title":"Biochim Biophys Acta"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-018-3368-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3368-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3368-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T19:55:47Z","timestamp":1557863747000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-018-3368-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,15]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["3368"],"URL":"https:\/\/doi.org\/10.1007\/s00277-018-3368-8","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,15]]},"assertion":[{"value":"16 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}